Small-animal PET of tumor damage induced by photothermal ablation with 64Cu-Bis-DOTA-hypericin

Journal of Nuclear Medicine

Volumn 52, Issue 5, 2011, Pages 792-799

  Song, Shaoli ^a,b   Xiong, Chiyi ^a   Zhou, Min ^a   Lu, Wei ^a   Huang, Qian ^a   Ku, Geng ^a   Zhao, Jun ^a   Flores Jr , Leo G ^a   Ni, Yicheng ^c   Li, Chun ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Cell damage; Hypericin; Near infrared (NIR); Neoplasm; Photothermal ablation therapy; Positron emission tomography

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; BIS 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; COPPER 64; COPPER SULFATE; HYPERICIN; NANOPARTICLE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLSERINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BREAST TUMOR; CONTROLLED STUDY; DRUG BINDING; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMAGE PROCESSING; IRRADIATION; ISOTOPE LABELING; LASER; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PHOTOTHERAPY; PHOTOTHERMAL ABLATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SUBCUTANEOUS TISSUE TUMOR; SURFACE PLASMON RESONANCE; TREATMENT RESPONSE; TUMOR ABLATION;

ABLATION TECHNIQUES; ANIMALS; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; MICE; MICE, NUDE; NANOPARTICLES; ORGANOMETALLIC COMPOUNDS; PEPTIDES; PERYLENE; PHOSPHATIDYLSERINES; POSITRON-EMISSION TOMOGRAPHY; SULFIDES; SURFACE PLASMON RESONANCE; TREATMENT OUTCOME;

EID: 79955764376     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.086116     Document Type: Article

References (33)

1. Fiedler VU, Schwarzmaier HJ, Eickmeyer F, Muller FP, Schoepp C, Verreet PR. Laser-induced interstitial thermotherapy of liver metastases in an interventional 0.5 Tesla MRI system: technique and first clinical experiences. J Magn Reson Imaging. 2001;13:729-737. (Pubitemid 32381850)
2. Vogel A, Venugopalan V. Mechanisms of pulsed laser ablation of biological tissues. Chem Rev. 2003;103:577-644.
3. Dewey WC. Arrhenius relationships from the molecule and cell to the clinic. Int J Hyperthermia. 1994;10:457-483. (Pubitemid 24224020)
4. Hirsch LR, Stafford RJ, Bankson JA, et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci USA. 2003;100:13549-13554. (Pubitemid 37444779)
5. Loo C, Lin A, Hirsch L, et al. Nanoshell-enabled photonics-based imaging and therapy of cancer. Technol Cancer Res Treat. 2004;3:33-40. (Pubitemid 38250466)
6. O'Neal DP, Hirsch LR, Halas NJ, Payne JD, West JL. Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett. 2004;209:171-176. (Pubitemid 38670486)
7. El-Sayed IH, Huang X, El-Sayed MA. Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett. 2006;239:129-135. (Pubitemid 43946581)
8. Skrabalak SE, Au L, Lu X, Li X, Xia Y. Gold nanocages for cancer detection and treatment. Nanomedicine (Lond). 2007;2:657-668. (Pubitemid 350268245)
9. 64Cu]CuS nanoparticle platform for simultaneous micro-PET/CT imaging and photothermal ablation therapy. J Am Chem Soc. 2010;132:15351-15358.
10. Li Y, Lu W, Huang Q, Huang M, Li C, Chen W. CuS nanoparticles for photothermal ablation of tumor cells. Nanomedicine (Lond). 2010;5:1161-1171.
11. 18F-FDG PET. J Nucl Med. 2009;50(suppl 1):97S-105S.
12. Saif MW, Tzannou I, Makrilia N, Syrigos K. Role and cost effectiveness of PET/CT in management of patients with cancer. Yale J Biol Med. 2010;83:53-65.
13. Frangioni JV. New technologies for human cancer imaging. J Clin Oncol. 2008;26:4012-4021.
14. 18F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer?. J Nucl Med. 2010;51:1344-1348.
15. 18F-FDG uptake within minutes after chemotherapy in a rabbit VX2 tumor model. J Nucl Med. 2008;49:303-309.
16. 18F-FDG PET/CT-related metabolic parameters and their value in early prediction of chemotherapy response in a VX2 tumor model. Nucl Med Biol. 2010;37:327-333.
17. Rosenbaum SJ, Lind T, Antoch G, Bockisch A. False-positive FDG PET uptake: the role of PET/CT. Eur Radiol. 2006;16:1054-1065.
18. Siegel BA, Dehdashti F. Oncologic PET/CT: current status and controversies. Eur Radiol. 2005;15(suppl 4):D127-D132. (Pubitemid 43091083)
19. Anderson CJ, Ferdani R. Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biother Radiopharm. 2009;24:379-393.
20. Karioti A, Bilia AR. Hypericins as potential leads for new therapeutics. Int J Mol Sci. 2010;11:562-594.
21. Van de Putte M, Wang H, Chen F, De Witte PA, Ni Y. Hypericin as a marker for determination of tissue viability after radiofrequency ablation in a murine liver tumor model. Oncol Rep. 2008;19:927-932. (Pubitemid 351802661)
22. 123I]iodohypericin micro-SPECT. Eur Heart J. 2008;29:260-269.
23. 123I] iodohypericin as a necrosis-avid tracer agent. Eur J Nucl Med Mol Imaging. 2006;33:595-601.
24. Vanderheyden JL, Liu G, He J, Patel B, Tait JF, Hnatowich DJ. Evaluation of 99mTc-MAG3-annexin V: influence of the chelate on in vitro and in vivo properties in mice. Nucl Med Biol. 2006;33:135-144. (Pubitemid 43184088)
25. Lu W, Zhang G, Zhang R, et al. Tumor site-specific silencing of NF-κB p65 by targeted hollow gold nanosphere-mediated photothermal transfection. Cancer Res. 2010;70:3177-3188.
26. Melancon M, Lu W, Li C. Gold-based magneto/optical nanostructures: challenges for in vivo applications in cancer diagnostics and therapy. Mater Res Bull. 2009;34:415-421.
27. Schempp CM, Winghofer B, Langheinrich M, Schopf E, Simon JC. Hypericin levels in human serum and interstitial skin blister fluid after oral single-dose and steady-state administration of Hypericum perforatum extract (St. John's wort). Skin Pharmacol Appl Skin Physiol. 1999;12:299-304. (Pubitemid 29401459)
28. Van de Putte M, Wang H, Chen F, de Witte PA, Ni Y. Hypericin as a marker for determination of tissue viability after intratumoral ethanol injection in a murine liver tumor model. Acad Radiol. 2008;15:107-113. (Pubitemid 350217024)
29. van den Boom MA, Wassink MG, Westerman J, et al. In vivo turnover of phospholipids in rabbit erythrocytes. Biochim Biophys Acta. 1994;1215:314-320.
30. Li MO, Sarkisian MR, Mehal WZ, Rakic P, Flavell RA. Phosphatidylserine receptor is required for clearance of apoptotic cells. Science. 2003;302:1560-1563. (Pubitemid 37475698)
31. Fadok VA, de Cathelineau A, Daleke DL, Henson PM, Bratton DL. Loss of phospholipid asymmetry and surface exposure of phosphatidylserine is required for phagocytosis of apoptotic cells by macrophages and fibroblasts. J Biol Chem. 2001;276:1071-1077. (Pubitemid 32096530)
32. Gaipl US, Beyer TD, Baumann I, et al. Exposure of anionic phospholipids serves as anti-inflammatory and immunosuppressive signal: implications for antiphospholipid syndrome and systemic lupus erythematosus. Immunobiology. 2003;207:73-81. (Pubitemid 36285099)
33. Fadeel B, Xue D, Kagan V. Programmed cell clearance: molecular regulation of the elimination of apoptotic cell corpses and its role in the resolution of inflammation. Biochem Biophys Res Commun. 2010;396:7-10.